Dare Bioscience (DARE) EV to CFO (2017 - 2025)

Dare Bioscience (DARE) has reported EV to CFO for 9 consecutive years, with 2.19 the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, EV to CFO fell 201.65% year-over-year to 2.19; the trailing twelve-month figure through Dec 2025 stood at 0.32 (down 84.85% YoY), and the FY2025 full-year result was 0.32, down 84.85% from the prior year.
• EV to CFO improved to 2.19 in Q4 2025 per DARE's latest filing, from 13.91 in the prior quarter.
• Across five years, EV to CFO topped out at 62.37 in Q3 2021 and bottomed at 13.91 in Q3 2025.
• Historically, EV to CFO has averaged 1.34 across 5 years, with a median of 4.14 in 2023.
• The sharpest annual moves came in 2021 and 2025: EV to CFO surged 1286.13% in 2021, then slumped 400.86% in 2025.
• Over 5 years, EV to CFO stood at 7.12 in 2021, then rose by 14.92% to 6.06 in 2022, then surged by 58.81% to 2.5 in 2023, then jumped by 186.43% to 2.16 in 2024, then tumbled by 201.65% to 2.19 in 2025.
• According to Business Quant data, EV to CFO over the past three periods registered 2.19, 13.91, and 3.07 for Q4 2025, Q3 2025, and Q2 2025 respectively.